The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of trabectedin, having considered evidence on the nature of advanced soft tissue sarcoma and the value placed ...

US-based biotechnology company Sonnet BioTherapeutics has expanded its Phase I SB101 study of SON-1010 for advanced solid tumours. The company is adding a cohort to assess the efficacy of SON-1010 ...

Combining trabectedin and olaparib showed marginal improvement in progression-free survival for advanced soft tissue sarcomas, with notable benefits in specific subgroups. Patients with PARP1 ...

For patients with metastatic or surgically unresectable leiomyosarcoma, combination therapy with doxorubicin and trabectedin is associated with improved overall and progression-free survival compared ...

PRINCETON, NJ, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, ...

Soft tissue sarcomas (STS) are a complex, heterogeneous group of more than 50 neoplasms of mesenchymal origin. According to the American Cancer Society, in 2015, approximately 11,930 patients in the ...

• Trabectedin injection should be given directly into the vein through a separate central venous line very slowly for 24 hours. • Trabectedin powder for reconstitution should be mixed with 20 ml of ...

Review the side-effects of Trabectedin as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Chicago and Madrid, June 1st 2015: PharmaMar today announced data from a Phase 2 study in patients with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2% (95% CI: 18.4-67.1) of ...

July 7, 2010 — Trabectedin (Yondelis) has been approved in Europe, Canada, and other regions of the world for use in platinum-sensitive recurrent ovarian cancer, but it is not available in the United ...

Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada ...